Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle et al.|Clinical Infectious Diseases|2023Cited by 27
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom et al.|Clinical Infectious Diseases|2023Cited by 23
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, H Appoyer, Lene Ryom et al.|Clinical Infectious Diseases|2020Cited by 22
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort SettingLauren Greenberg, A Tavelli, Katharina Kusejko et al.|Open Forum Infectious Diseases|2022Cited by 5
Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort StudyOlof Elvstam, Alessandro Tavelli, Lene Ryom et al.|Open Forum Infectious Diseases|2025Cited by 4